Why the study?
Mutations in the cardiac splicing factor RBM20 lead to malignant DCM, but the underlying mechanisms remained to be understood.
Population
Isogenic iPSCs and iPSC-derived engineered heart tissues with DCM-associated RBM20 missense mutations or RBM20 KO
Comparison
RBM20 missense mutations vs RBM20 KO
Design
Preclinical in vitro mechanistic study
Authors
Loading...
Warrants mutation-specific models in RBM20 cardiomyopathy; leaves open human translation from preclinical data.
RBM20 missense mutations drive dilated cardiomyopathy via a gain-of-function mechanism involving altered RNA binding and cytoplasmic mislocalization, distinct from simple loss of function.
Fenix et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: